Cross Icon

Evernorth EncircleRxSM

Discover EncircleRx, a data-driven portfolio that helps plan sponsors reduce costs and enhance outcomes. EncircleRx: Cardiodiabesity gives clients optionality and predictability in managing cardiodiabesity — obesity, diabetes and cardiovascular disease — with the first-ever GLP-1 financial guarantee from a PBM.

Cross Icon
Cross Icon
Cross Icon
Learn how EncircleRx can help you manage the cost of GLP-1s.
EncircleRx: Cardiodiabesity offers the PBM industry's first financial guarantee, giving plans the tools to better control GLP-1 growth and expand access.
Cross Icon
Cross Icon

What is Cardiodiabesity?

The connection linking obesity, diabetes and cardiovascular disease

Many Americans struggle with obesity and are seeking new ways to lose weight to improve their overall health, even if it means using off-label medications which are in short supply for those who desperately need them.

Up to 53% of new type 2 diabetes cases in the U.S. today are linked to obesity, meaning that over half of diabetes cases could be prevented by more effective obesity treatment.2

Of those diagnosed with type 2 diabetes, 77% have high cholesterol and/or high blood pressure, putting them at risk for a third, potentially fatal comorbidity: cardiovascular disease.3

Cardiodiabesity is a hybrid term that describes the relationship between obesity, type-2 diabetes and cardiovascular disease. It’s becoming a widely recognized and urgent concern among health care researchers, providers, plans and most of all, patients.

1. CDC, 2021.
2. American Heart Association, 2021.
3. 2023 Drug Trend Report data.

Woman looking down and listening to her pulse while timing it with wrist watch

Cardiodiabesity affects health care costs as one of the most expensive condition categories to treat.


annual U.S. medical costs for obesity4



4. CDC, 2022, resources/publications/factsheets/nutrition.html


the cost of diagnosed diabetes in one year6



6. CDC, 2021,


annual cost of health care services, medications and productivity loss due to heart disease5


5. CDC, 2021, healthtopics/heartdisease/index.htm

Cardiodiabesity is complicated…but its benefits management doesn’t have to be.

Addressing the complexity of these conditions requires a tailored, data-driven and innovative approach to both decrease pharmacy spend and save lives.

Evernorth’s transparent, proactive and innovative capabilities come together to help plans manage cardiodiabesity, unlocking a benefit that tackles this high-cost and highly prevalent disease category in a more streamlined way.

Cardiodiabesity is the first solution from the EncircleRx portfolio and provides optionality to manage trend and improve patient outcomes.

woman exercising

Tackling the GLP-1 Trend

GLP-1s are effective in treating the progression of diseases that stem from obesity: diabetes and cardiovascular disease. The GLP-1 class of drugs is on tap to be the number one trend for plans this year. In fact, J.P. Morgan Research forecasts that the GLP-1 market will exceed $100B by 2030, driven equally by diabetes and obesity usage.7

Clients want to make weight loss coverage part of the benefit, but are unsure of how to navigate this costly landscape.

The first-ever GLP-1 financial guarantee available from a PBM

EncircleRx now offers financial guarantees to provide plans with greater predictability and control of GLP-1 spend through a cost cap or savings guarantee depending on client type.

Learn more about our new GLP-1 management capabilities here.

7. J.P. Morgan, 2023.

Changing the narrative with enhanced care delivery

Managing GLP-1s for weight loss and diabetes is just one component of EncircleRx.
Close gaps in care

and delay or prevent the onset of comorbid conditions, reducing the need for interventions.

Combat costs

with personalized recommendations that identify both clinical and financial opportunities during treatment of these costly conditions. 

Improve outcomes

through a combination of plan design, innovative measures and utilization management considerations.

Explore more about cardiodiabesity and GLP-1s
Cross Icon
Cross Icon
Want to learn more?
Please contact your account representative or consultant relations director to learn how Evernorth can help provide optionality in managing cardiodiabesity trend.
Cross Icon
Cross Icon